Skip to main content
. Author manuscript; available in PMC: 2013 Oct 9.
Published in final edited form as: Ann Intern Med. 2011 Jul 19;155(2):69–79. doi: 10.7326/0003-4819-155-2-201107190-00002

Base-Case Costs and Ranges for Variables in the Model*

Variable Base-Case Cost, $ Range in Sensitivity Analyses, $ γ Distributions for Monte Carlo Simulations
References
α λ
Cost of administering clinical criteria 50 40–60 11.11 0.22 90

Cost of tumor testing
BRAF testing 110 88–132 13.44 0.12 50

 IHC 280 224–336 31.36 0.112 50

 MSI 490 392–588 15.37 0.031 50
Cost of genetic testing and genetic counseling

 Germline test for 1 gene 880 600–1200 19.36 0.022 50

 Single-site mutation testing 460 200–475 9.40 0.020 50

 Approaching relative to offer genetic testing 110 88–132 13.44 0.122 50

 Initial genetic counseling visit 185 148–222 38.03 0.206 50

 Follow-up genetic counseling visit 105 84–126 12.25 0.117 50

Cost of screening and complications
 Colonoscopy 645 516–774 41.60 0.06 91
 Colonoscopy complications

  Bleeding 6218 4974–7462 17.18 0.003 90, 91

  Perforation 10 304 8243–12 365 26.54 0.003 90, 91

 Polypectomy and pathology 235 188–282 22.09 0.094 91

 Endometrial biopsy 224 179–269 13.94 0.062 91

 Transvaginal ultrasonography 110 88–132 13.44 0.012 91

Cost of risk-reducing surgeries
 TAH-BSO 16 348 13 078–19 618 42.76 0.003 92

 Subtotal colectomy 14 059 11 247–16 871 31.62 0.002 90, 91

Cost of colorectal cancer care in patients who do not have the Lynch syndrome
 Without screening
  Initial 43 471 34 777–52 165 18.90 0.0004 93

  Year 1 3496 2797–4195 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 2 3184 2547–3821 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 3 3002 2402–3602 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 4 2904 2323–3485 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 5 2845 2276–3414 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  In year of death 52 440 41 952–62 928 27.50 0.0005 93
 With screening

  Initial 38 711 30 969–46 453 14.99 0.0004 93

  Year 1 2978 2382–3574 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 2 2801 2241–3361 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 3 2701 2161–3241 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 4 2647 2118–3176 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 5 2615 2092–3138 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  In year of death 50 930 40 744–61 116 25.94 0.0005 93
Cost of colorectal cancer care in patients with the Lynch syndrome
 Without screening
  Initial 38 568 30 854–46 282 14.87 0.0004 93

  Year 1 3060 2448–3672 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 2 2839 2271–3407 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 3 2715 2172–3258 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 4 2649 2119–3179 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 5 2610 2088–3132 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  In year of death 51 978 41 582–62 374 27.02 0.0005 93
 With screening

   Initial 33 711 26 969–40 453 11.36 0.0003 93

  Year 1 2457 1966–2948 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 2 2447 1958–2936 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 3 2439 1951–2927 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 4 2433 1946–2920 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  Year 5 2428 1942–2914 Not varied in sensitivity analyses Not varied in sensitivity analyses 93

  In year of death 49 210 39 368–59 052 24.22 0.0005 93

Cost of cancer care
 Endometrial cancer 31 027 24 822–37 232 15.04 0.0005 92

 Ovarian cancer 32 379 25 903–38 855 10.48 0.0003 94

IHC = immunohistochemistry; MSI = microsatellite instability; TAH-BSO = total abdominal hysterectomy and bilateral salpingo-oophorectomy.

*

All costs are in 2010 U.S. dollars.

Amsterdam II criteria, revised Bethesda Guidelines, or prediction models (MMRpredict, MMRpro, and PREMM[1,2,6]).

HHS Vulnerability Disclosure